Milken Institute launches vaccine development and treatment tracker for COVID-19

NewsGuard 100/100 Score

The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.

The tracker is available online at https://milkeninstitute.org/covid-19-tracker. It is developed and maintained by FasterCures, a center of the Milken Institute, with an Advisory Council comprised of a Nobel Laureate researcher, former FDA chiefs, and industry leaders.

We seek to accelerate efforts to find new treatments or vaccines, amplify what's working, hold the system and its players accountable, and expand the global discussion about how to create durable, long term solutions. COVID-19 is putting that approach to the test. We hope to be a resource promoting effective approaches and strategies."

Esther Krofah, executive director of FasterCures

The Milken Institute COVID-19 vaccine development and treatment tracker is compiled from publicly available sources. It will grow to include FDA-approved indications where applicable, as well as basic information about the focus of each clinical trial.

The information in the tracker is current as of March 18, 2020. The Milken Institute welcomes input on new treatments and vaccines in development. Please email [email protected] with tips.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies